Crossmark

Early Growth Response 3 regulates genes of inflammation and directly activates IL6 and IL8 expression in prostate cancer

Crossref DOI link: https://doi.org/10.1038/bjc.2014.622

Published Online: 2015-01-29

Published Print: 2015-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Baron, V T

Pio, R

Jia, Z

Mercola, D
License Information

License valid from 2015-01-29
More Information

Article History

Received: 12 August 2014

Revised: 14 November 2014

Accepted: 20 November 2014

First Online: 29 January 2015

Competing interests

: D Mercola is a stockholder of Proveri Inc. of San Diego, a biotechnology start-up company developing prostate cancer-related tests. VT Baron is a consultant for PellFiCure Pharmaceuticals, Inc., a company that develops combination therapies for prostate cancer.